Annexin Pharmaceuticals AB (publ) (STO:ANNX)

Sweden flag Sweden · Delayed Price · Currency is SEK
14.80
-0.10 (-0.67%)
Feb 11, 2026, 1:44 PM CET
Market Cap105.18M -59.7%
Revenue (ttm)n/a
Net Income-36.89M
EPS-5.58
Shares Out7.06M
PE Ration/a
Forward PE5.37
Dividendn/a
Ex-Dividend Daten/a
Volume5,657
Average Volume6,304
Open15.30
Previous Close14.90
Day's Range14.00 - 15.30
52-Week Range13.50 - 42.70
Beta0.08
RSI40.11
Earnings DateFeb 6, 2026

About STO:ANNX

Annexin Pharmaceuticals AB (publ), a clinical stage biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. It develops ANXV, a human recombinant protein and Annexin A5, natural protein that protects and repairs cells, as well as counteract unwanted inflammatory and immune cell reactions. Annexin Pharmaceuticals AB (publ) was incorporated in 2014 and is based in Stockholm, Sweden. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 4
Stock Exchange Nasdaq Stockholm
Ticker Symbol ANNX
Full Company Profile

Financial Performance

Financial Statements